Biography:
Prof. Qing Xu, MD, PhD, is Vice President and Director of Medical Oncology at Shanghai Mengchao Cancer Hospital, Shanghai University, and Chief Expert of Oncology at Shanghai Tenth People’s Hospital, Tongji University. He is a doctoral supervisor and Shanghai Pujiang Talent, specializing in tumor immunotherapy, targeted therapy, and comprehensive treatment of solid malignancies. He has published nearly 100 SCI papers in leading journals including Science Advances, Oncogene, and Signal Transduction and Targeted Therapy (STTT). He serves as Vice President of China Medical Education Association and Vice Chairman of China Medicinal Biotechnology Association.
Title : Phase I dose-escalation study of nanobody-armored Dendritic Cell Vaccine (Baize DC) in patients with solid tumors after radical resection